ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

JAZZ Jazz Pharmaceuticals PLC

109.53
0.70 (0.64%)
Last Updated: 12:36:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 122,610
Bid Price 109.55
Ask Price 109.62
News -
Day High 110.44

Low
106.605

52 Week Range

High
146.70

Day Low 109.46
Company Name Stock Ticker Symbol Market Type
Jazz Pharmaceuticals PLC JAZZ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.70 0.64% 109.53 12:36:01
Open Price Low Price High Price Close Price Prev Close
109.72 109.46 110.44 108.83
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,212 122,610 $ 109.94 $ 13,479,193 - 106.605 - 146.70
Last Trade Time Type Quantity Stock Price Currency
12:35:59 1 $ 109.5876 USD

Jazz Pharmaceuticals PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.86B 62.35M - 3.83B 414.83M 6.65 16.53
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Jazz Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No JAZZ Message Board. Create One! See More Posts on JAZZ Message Board See More Message Board Posts

Historical JAZZ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week110.53111.35106.605108.86594,685-1.00-0.90%
1 Month120.60121.53106.605114.08603,040-11.07-9.18%
3 Months127.57134.17106.605119.63613,708-18.04-14.14%
6 Months131.70134.48106.605121.21650,555-22.17-16.83%
1 Year145.06146.70106.605126.17605,935-35.53-24.49%
3 Years166.57189.00106.605141.56591,735-57.04-34.24%
5 Years126.59189.0086.88139.08593,164-17.06-13.48%

Jazz Pharmaceuticals Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Your Recent History

Delayed Upgrade Clock